(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 2 October 2003 (02.10.2003)

PCT

(10) International Publication Number WO 03/080825 A2

- (51) International Patent Classification⁷: C12N 9/12, 15/54, C12Q 1/48, G01N 33/50, 33/53, A61K 39/00, 38/00
- (21) International Application Number: PCT/EP03/02902
- (22) International Filing Date: 20 March 2003 (20.03.2003)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/367,512 27 March 20 60/406,936 30 August 20

27 March 2002 (27.03.2002) US 30 August 2002 (30.08.2002) US

- (71) Applicant (for all designated States except US): BAYER AKTIENGESELLSCHAFT [DE/DE]; 51368 Leverkusen (DE).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): LIOU, Jiing-Ren [CN/US]; 10 Winslow Road, Belmont Road, MA 02478 (US).
- (74) Common Representative: BAYER AKTIENGE-SELLSCHAFT; 51368 Leverkusen (DE).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: REGULATION OF HUMAN BMP-2 INDUCIBLE KINASE

(57) Abstract: Reagents that regulate human BMP-2 inducible kinase and reagents which bind to human BMP-2 inducible kinase gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, cancer, diabetes, CNS disorders, COPD, gastrointestinal disorders, and cardiovascular disorders.



(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 2 October 2003 (02.10.2003)

(10) International Publication Number WO 2003/080825 A3

- C12N 9/12, (51) International Patent Classification7: 15/54, C12Q 1/48, G01N 33/50, 33/53, A61K 39/00, 38/00
- (21) International Application Number:

PCT/EP2003/002902

- (22) International Filing Date: 20 March 2003 (20.03.2003)
- (25) .. Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/367,512

US 27 March 2002 (27.03.2002)

US 60/406,936 30 August 2002 (30.08.2002)

- (71) Applicant (for all designated States except US): BAYER HEALTHCARE AG [DE/DE]; 51368 Leverkusen (DE).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): LIOU, Jiing-Ren [CN/US]; 10 Winslow Road, Belmont Road, MA 02478 (US).
- (74) Common Representative: BAYER HEALTHCARE AG; Law and Patents, Patents and Licensing, 51368 Leverkusen (DE).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH. CN. CO. CR. CU. CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OART Scient (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, M, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

Published:

- with international search report
- (88) Date of publication of the international search report: 18 March 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: FURTHER BMP-2 INDUCIBLE KINASES AND THE USES THEREOF

(57) Abstract: Reagents that regulate human BMP-2 inducible kinase and reagents which bind to human BMP-2 inducible kinase gene products may play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, cancer, diabetes, CNS disorders, COPD, gastrointestinal disorders, and cardiovascular disorders.

INTERMITIONAL SEARCH REPORT

Internation ication No PCT/EP 02902

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12N9/12 C12N15/54 A61K39/00

A61K38/00

C12Q1/48

G01N33/50

G01N33/53

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C12N C12Q G01N A61K C07K IPC 7

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

MEDLINE, EPO-Internal, EMBL, BIOSIS, WPI Data, PAJ, CHEM ABS Data, EMBASE

	MENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with Indication, where appropriate, of	the relevant passages	Relevant to claim No.
x	WO 00 21976 A (GEN HOSPITAL CO 20 April 2000 (2000-04-20) abstract SEQ ID NO.: 2 page 4, line 21 - line 27 page 18, line 24,FF. page 23, line 13,FF. page 33; claims 3-22	ORP)	1-17
Special of A docum cons E earlier filling L docum which citation of docum other producer later	rther documents are listed in the continuation of box C. categories of cited documents: ment defining the general state of the art which is not sidered to be of particular relevance r document but published on or after the international date ment which may throw doubts on priority claim(s) or the is cited to establish the publication date of another ion or other special reason (as specified) ment referring to an oral disclosure, use, exhibition or r means ment published prior to the international filling date but than the priority date claimed e actual completion of the international search	*T* later document published after the or priority date and not in conflicted to understand the principl invention. *X* document of particular relevance cannot be considered novel or involve an inventive step when. *Y* document of particular relevance cannot be considered to involve document is combined with on ments, such combination being in the art. *&* document member of the same Date of mailing of the internation	he international filing date ict with the application but ie or theory underlying the e; the claimed invention cannot be considered to the document is taken alone e; the claimed invention e an inventive step when the e or more other such docugo bylous to a person skilled
	17 September 2003	Authorized officer	

INTERMITIONAL SEARCH REPORT

Internation No PCT/EP 2902

C(Cantin	tion) DOCUMENTS CONSIDERED TO BE RELEVANT	101/11 032902
Category °		Relevant to claim No.
		1-17
X	KEARNS A E ET AL: "Cloning and characterization of a novel protein kinase that impairs osteoblast differentiation in vitro." THE JOURNAL OF BIOLOGICAL CHEMISTRY.	1-17
	UNITED STATES 9 NOV 2001, vol. 276, no. 45, 9 November 2001 (2001-11-09), pages 42213-42218, XP002250920	
	ISSN: 0021-9258 abstract page 42215; figure 2	
	Introduction page 42213 -page 42214 Discussion page 42217 -page 42218	
X	WO 01 77150 A (MERCK PATENT GMBH ;GUESSOW DETLEF (DE); SCHARM BURKHARD (DE)) 18 October 2001 (2001-10-18) SEQ ID NOs: 3 and 4 abstract	1–17
X	WO 01 53312 A (CHEN RUI HONG ;GOODRICH RYLE (US); HYSEQ INC (US); WANG DUNRUI (US) 26 July 2001 (2001-07-26) SEQ ID NO.: 2577	1–17
X	WO 01 38503 A (PLOWMAN GREGORY D ;CLARY DOUGLAS (US); SUGEN INC (US); WHYTE DAVID) 31 May 2001 (2001-05-31) Protein SGK419 ID#AA92	1–17
Х,Р	WO 02 083709 A (TANG Y TOM; INCYTE GENOMICS INC; RECIPON SHIRLEY A (US); BURRILL J) 24 October 2002 (2002-10-24) abstract page 102; table 2 SEQ ID NOS: 1 AND 16	1-17
Х,Р	DATABASE EMBL 'Online! EBI; 24 September 2002 (2002-09-24) STRAUSBERG: "Homo sapiens, Similar to BMP-2 inducible kinase" retrieved from EMBL Database accession no. BC036021 XP002250921 the whole document	1–17



Internation PC P 03/02902

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. X Claims Nos.: 8,9,13-17(partly) because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically: see FURTHER INFORMATION sheet PCT/ISA/210
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This international Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-17 (partly)
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 8,9,13-17(partly)

Present claims 8,9,13-17 relate to a compound/method defined by reference to a desirable characteristic or property, namely to reagent which specificall interacts with polypeptide or polynucleotide of BMP-2 inducible kinase or modulate the activity thereof

The claims cover all methods/componds/uses having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds/methods. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound/method/uses by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds which are specific antibodies and anti-search poly-/oligo-nucleoties.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-17(partly)

An isolated polynucleotide being selected from the group consisting of: a polynucleotide encoding BMP-2 inducible kinase polypeptide comprising an amino acid sequence selsected from the group consisting of:

- a)
 amino acid sequences which are at least 72% identical
 to the amino acid sequence shown in SEQ ID NO.: 2 and
- ii. the amino acid sequence shown in SEQ ID NO.: 2
- b) a polynucleotide comprising the sequence of SEQ ID NOs: 1 or 3
- c)
 a polynucleotide which hybridises under stringent conditions
 to a polynucleotide specified in a) and b), and which
 encodes said amir and sid sequences;
- d)
 a polynucleotide the sequence of which deviates from from
 the polynucleotide sequence specified above due to the
 degeneration of the genetic code and which encodes said
 amino acid sequence;
- e)
 a polynucleotide which represents a fragment, derivative or
 allelic variation of the polynuceleotide specified above and
 which encodes said amino acid sequence.

The subject matter of dependent claims 2-17 in relation of the isolated polynuceleotide as above.

2. Claims: 1-17(partly)

An isolated polynucleotide being selected from the group consisting of: a polynucleotide encoding BMP-2 inducible kinase polypeptide comprising an amino acid sequence selsected from the group consisting of:

- a) amino acid sequences which are at least 72% identical to the amino acid sequence shown in SEQ ID NO.: 4 and
- ii. the amino acid sequence shown in SEQ ID NO.: 4
- b) a polynucleotide which hybridises under stringent conditions

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

to a polynucleotide specified in a), and which encodes said amino acid sequences;

- c) a polynucleotide the sequence of which deviates from from the polynucleotide sequence specified above due to the degeneration of the genetic code and which encodes said amino acid sequence;
- d)
 a polynucleotide which represents a fragment, derivative or
 allelic variation of the polynuceleotide specified above and
 which encodes said amino acid sequence.

The subject matter of dependent claims 2-17 in relation of the isolated polynuceleotide as above.

INTERNATIONAL SEARCH REPORT Information tent family members

Internation Catlon No
PCT/EP 02902

•				PCI/EF	02902
Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0021976	A	20-04-2000	AU	6519299 A	01-05-2000
1	••		CA	2345885 A1	20-04-2000
			EP	1121374 A1	08-08-2001
			JP	2002527053 T	27-08-2002
			WO	0021976 A1	20-04-2000
WO 0177150	Α	18-10-2001	CA	2405730 A1	18-10-2001
			WO	0177150 A2	18-10-2001
			ΕP	1272641 A2	08-01-2003
			JP	2003530122 T	14-10-2003
WO 0153312	Α	26-07-2001	US	6569662 B1	27-05-2003
			AU	2292401 A	31-07-2001
			AU	2591801 A	31-07-2001
			AU	2593601 A	31-07-2001
			AU	2595501 A	31-07-2001
			AU	2596501 A	31-07-2001
			AU	2598301 A	31-07-2001
			AU	2728401 A 2734401 A	31-07-2001 31-07-2001
			AU	2734401 A 2734801 A	31-07-2001
			AU AU	2734601 A 2738501 A	31-07-2001
			AU	3265701 A	31-07-2001
			CA	2395443 A1	26-07-2001
			CA	2395731 A1	26-07-2001
			CA	2395736 A1	26-07-2001
			CA	2395749 A1	26-07-2001
1			CA	2395763 A1	26-07-2001
			CA	2395770 A1	26-07-2001
			CA	2402563 A1	26-07-2001
			EΡ	1242596 A1	25-09-2002
			EP	1240178 A2	18-09-2002
			EP	1242580 A1	25-09-2002
			EP	1242443 A1	25-09-2002
			EP	1250346 A2	23-10-2002
			EP	1254256 A2	06-11-2002 16-10-2002
			EP	1248848 A1	26-07-2002
			WO WO	0153312 A1 0153453 A2	26-07-2001
			WO	0153455 A2 0153326 A1	26-07-2001
			WO	0153320 A1 0153454 A2	26-07-2001
			WO	0153455 A2	26-07-2001
			WO	0153456 A2	26-07-2001
			WO	0153466 A1	26-07-2001
			WO	0152616 A2	26-07-2001
			WO	0153500 A1	26-07-2001
			WO	0153515 A1	26-07-2001
			WO	0153485 A1	26-07-2001
1			US	2003104529 A1	05-06-2003
			US	2003211987 A1	13-11-2003
			US	6586390 B1	01-07-2003
			US	6465620 B1	15-10-2002
			US	2002146692 A1	10-10-2002
İ		•	AU	5362001 A	30-10-2001 35-10-2001
1			CA	2406039 A1	25-10-2001 22-01-2003
1			EP	1276754 A2 0179446 A2	25-10-2001
			WO US	2002197679 A1	26-12-2002
			U3	LUCLISIONS RI	
	1.40001				

INTERNATIONAL SEARCH REPORT Informatio tent family members

Internation Vication No
PCT/EP J2902

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 0153312	Α		US	2002142953	A1	03-10-2002
WO 0138503	A	31-05-2001	AU CA EP JP WO	1926001 / 2394803 / 1240194 / 2003514583 / 0138503 /	A1 A2 T	04-06-2001 31-05-2001 18-09-2002 22-04-2003 31-05-2001
WO 02083709	Α	24-10-2002	WO	02083709	A2	24-10-2002

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

= 110111 = 1110 min
☐ BLACK BORDERS
IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
☐ LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

☐ OTHER:

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.